AMI Pharm Advances AYP-101 to Phase 3 Redefining Injectable Fat Reduction Drug for Patient Comfort AMI Pharm's innovative injectable drug AYP-101 moves into Phase 3 trials, promising enhanced fat reduction with reduced discomfort for patients.

AMI Pharm Advances AYP-101 to Phase 3 Redefining Injectable Fat Reduction Drug for Patient Comfort #South_Korea #Seoul #AMI_Pharm #AYP-101 #Injectable_Drug